Targeting a Blinding Disease with CSB-001
Our lead candidate, CSB-001 (oremepermin alfa ophthalmic solution), has the potential to advance the treatment of corneal diseases by addressing the underlying drivers of vision loss in limbal stem cell deficiency (LSCD) patients. Our approach harnesses the multiple mechanisms of action of oremepermin alfa to promote corneal epithelial regeneration and cell survival, inhibits inflammation and scarring. With CSB-001, patient care can potentially be elevated beyond symptomatic disease management to the improvement of vision via a convenient eye drop.
CSB-001 (oremepermin alfa ophthalmic solution)
Multiple Mechanisms in One Drop to Fight LSCD
CSB-001 (oremepermin alfa ophthalmic solution) is Claris Bio’s lead investigational therapy and is designed to target the underlying pathophysiology of limbal stem cell deficiency (LSCD). Designed as a topical ocular biologic therapy for convenient administration, CSB-001 has the potential to provide a transformative treatment option beyond palliative care or surgery for patients with severe eye disease. Current surgical approaches are limited to specialized centers and may require long-term systemic immunosuppression and have variable outcomes, underscoring the need for innovative, earlier, and accessible treatment options.
CSB-001’s active moiety, oremepermin alfa, is a recombinant form of the naturally occurring human protein deleted hepatocyte growth factor (dHGF) involved in tissue repair. dHGF’s regenerative activities play an important role in maintaining corneal health and supporting healing. We believe the multiple mechanisms of action are the basis for the positive data observed with LSCDs patients to date in our studies, and support CSB-001’s advancement into pivotal studies in 2027.